US6087098A - Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma - Google Patents
Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma Download PDFInfo
- Publication number
- US6087098A US6087098A US08/839,698 US83969897A US6087098A US 6087098 A US6087098 A US 6087098A US 83969897 A US83969897 A US 83969897A US 6087098 A US6087098 A US 6087098A
- Authority
- US
- United States
- Prior art keywords
- cdna
- renal
- cell carcinoma
- human
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000006265 Renal cell carcinoma Diseases 0.000 title claims abstract description 58
- 238000003556 assay Methods 0.000 title abstract description 32
- 102100034343 Integrase Human genes 0.000 title description 11
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 title description 11
- 239000002299 complementary DNA Substances 0.000 claims abstract description 96
- 238000000034 method Methods 0.000 claims abstract description 33
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract description 24
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 19
- 239000011886 peripheral blood Substances 0.000 claims abstract description 19
- 239000013615 primer Substances 0.000 claims description 51
- 108020004999 messenger RNA Proteins 0.000 claims description 36
- 239000000523 sample Substances 0.000 claims description 19
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 12
- 230000003321 amplification Effects 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 239000003155 DNA primer Substances 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 239000002751 oligonucleotide probe Substances 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 58
- 230000014509 gene expression Effects 0.000 abstract description 50
- 102000004169 proteins and genes Human genes 0.000 abstract description 48
- 238000001514 detection method Methods 0.000 abstract description 17
- 208000009060 clear cell adenocarcinoma Diseases 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 238000012544 monitoring process Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 43
- 239000000203 mixture Substances 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 26
- 206010038389 Renal cancer Diseases 0.000 description 21
- 208000008839 Kidney Neoplasms Diseases 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 238000010240 RT-PCR analysis Methods 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 17
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 14
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 14
- 201000010982 kidney cancer Diseases 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000000499 gel Substances 0.000 description 13
- 239000003550 marker Substances 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 238000002105 Southern blotting Methods 0.000 description 9
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 8
- 229960005542 ethidium bromide Drugs 0.000 description 8
- 230000003211 malignant effect Effects 0.000 description 8
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 7
- 201000010174 renal carcinoma Diseases 0.000 description 7
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000005084 renal tissue Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 108020003215 DNA Probes Proteins 0.000 description 5
- 239000003298 DNA probe Substances 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000013059 nephrectomy Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000000439 tumor marker Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- SYHNZXHNEJUCJR-JGWLITMVSA-N aldehydo-D-glucose 3-phosphate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](O)C=O SYHNZXHNEJUCJR-JGWLITMVSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- JIONSDIFUGDYLD-UHFFFAOYSA-N diaminomethylideneazanium;phenol;thiocyanate Chemical compound [S-]C#N.NC([NH3+])=N.OC1=CC=CC=C1 JIONSDIFUGDYLD-UHFFFAOYSA-N 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Definitions
- the process of tumor detection and staging has been greatly improved by the development of assays that detect and measure tumor-specific markers in specimens of patient tissues or body fluids.
- PSA prostate specific antigen
- such assays have the potential of revolutionizing the clinical approach to diagnosis, staging and monitoring the effect of therapeutic intervention in human malignancies.
- Many of these tumor marker assays are based on immunologic detection of the tumor marker protein.
- tumor detection methods that involve DNA- and RNA-based assays of patient specimens are being used (2,3,4) .
- PCR polymerase chain reaction
- kidney cancer With regard to kidney cancer, it is estimated that 28,800 new cases will be diagnosed in 1997, resulting in approximately 11,700 deaths (8). The majority of deaths will be caused by renal cell carcinoma. If renal cell carcinoma tumors are detected while still confined to the kidney, radical nephrectomy results in excellent long term survival. Unfortunately, symptoms of disease rarely occur prior to metastatic spread. Once renal cell carcinoma has metastasized, survival rates are less than 100 at five years (9). Until now, no suitable diagnostic marker existed for renal cell carcinoma detection, staging or for monitoring the effect of therapy.
- This invention provides a PCR-based technique to detect the malignant renal cell marker MN in a peripheral blood sample.
- the MN protein was first detected on the cell surface of the highly-malignant cervical cancer cell line, HeLa (10). MN expression has also been detected in human cervical and ovarian tumor specimens, but not in normal cervical or ovarian tissue. These results suggested that MN might be a useful marker for screening certain gynecological malignancies (11). In these early studies, MN expression was also detected in normal epithelial cells of the gastric mucosa. Its restricted expression in this normal tissue was viewed as unlikely to interfere with tumor-specific detection in tissues outside of the gastrointestinal tract (11,12).
- the assay is useful for the diagnosis and molecular staging of renal cell carcinoma.
- the assay is also useful for the follow-up of renal cell carcinoma therapy.
- the assay is particularly sensitive for detection of a subset of renal cell carcinoma known as clear cell carcinoma. Quite importantly, the assay is capable of detecting the renal cell carcinoma marker MN in a peripheral blood test.
- This invention provides methods of: (a) diagnosing; (b) determining the stage of; and (c) monitoring the effect of a therapeutic intervention for a renal cell carcinoma in a human subject which comprises detecting the expression of the MN gene.
- the method is directed to detection of the renal cell carcinoma known as clear cell carcinoma.
- the method is used as a peripheral blood assay.
- the method is a polymerase chain reaction assay for amplifying and detecting the presence of the CDNA molecule encoding the MN protein.
- FIGS. 1A-1B MN expression in HeLa cell line and normal human tissue libraries.
- FIG. 1B The RT-PCR assay detects expression of MN (386 bp) in the HeLa cell line. No MN expression is seen in cDNA libraries from human heart, kidney, lung, muscle, placenta or brain. MN expression is seen in the human pancreas and liver.
- FIG. 1A Human glucose 3-phosphate dehydrogenase (G3-PDH) primers were utilized in a parallel reaction to amplify a 451 bp G3-PDH fragment to confirm mRNA integrity.
- G3-PDH Human glucose 3-phosphate dehydrogenase
- FIGS. 2A-2B MN expression in renal carcinoma cell lines.
- FIG. 2B The RT-PCR assay detects MN expression in renal carcinoma cell lines SKRC-01, SKRC-08 and SKRC-09. No MN expression is detected in cell lines SKRC-17, SKRC-39 and SKRC-42.
- FIG. 2A G3-PDH controls as in FIG. 1A.
- FIGS. 3A-3B MN expression in tissue from renal carcinoma patients.
- FIG. 3B The RT-PCR assay detects MN expression in tumor tissue from four renal tumor specimens (patients VM, MP, NR and DO) but does not detect MN expression in normal renal tissue taken from the ipsilateral kidney in the same four patients.
- FIG. 3A G3-PDH controls as in FIG. 1A.
- FIG. 4. MN expression in peripheral blood samples from: (a) normal human subjects; (b) patients with localized renal cell carcinoma (RCC); and (c) patients with metastatic RCC.
- RCC renal cell carcinoma
- This invention provides a method for diagnosing a clear cell renal carcinoma in a human subject which comprises: (a) obtaining mRNA from a sample of the subject's peripheral blood; (b) preparing cDNA from the mRNA from step (a); (c) amplifying DNA encoding MN present in the cDNA prepared in step (b); and (d) detecting the presence of any resulting amplified DNA, the presence of such amplified DNA being diagnostic for clear cell renal carcinoma.
- amplification of DNA encoding MN is effected by a polymerase chain reaction utilizing at least two oligonucleotide primers.
- each of the primers is capable of specifically hybridizing with DNA encoding MN.
- the primers comprise oligonucleotides having the sequence 5'-GGGACAAAGAAGGGGATGAC-3' (SEQ ID NO:1) and 5'-AAAGGCGCTGAGGTGAA-3' (SEQ ID NO:2).
- the presence of any amplified DNA in step (d) is detected using a labeled oligonucleotide probe which specifically hybridizes with the amplified DNA.
- the labeled probe is radiolabeled with 32 P.
- This invention provides a method for determining the stage of a clear cell renal carcinoma in a human subject which comprises: (a) obtaining mRNA from a sample of the subject's peripheral blood; (b) preparing cDNA from the mRNA from step (a); (c) amplifying DNA encoding MN present in the cDNA prepared in step (b); (d) determining the amount of any resulting amplified DNA; and (e) comparing the amount of amplified DNA determined in step (d) with the amount of amplified DNA indicative of each stage of clear cell renal carcinoma so as to thereby determine the stage of the clear cell renal carcinoma in the human subject.
- amplification of DNA encoding MN is effected by a polymerase chain reaction utilizing at least two oligonucleotide primers.
- each of the primers is capable of specifically hybridizing with DNA encoding MN.
- the primers comprise oligonucleotides having the sequence 5'-GGGACAAAGAAGGGGATGAC-3' (SEQ ID NO:1) and 5'-AAAGGCGCTGAGGTGAA-3' (SEQ ID NO:2).
- the presence of any amplified DNA in step (d) is detected using a labeled oligonucleotide probe which specifically hybridizes with the amplified DNA.
- the labeled probe is radiolabeled with 32P.
- This invention provides a method for monitoring the progression of a clear cell renal carcinoma in a human subject which comprises: (a) determining the stage of the clear cell renal carcinoma in the human subject at a first time according to the method of claim 7; (b)determining the stage of the clear cell renal carcinoma in the human subject at a subsequent time or times; and (c) comparing the stage determined in (a) with the stage determined in (b) so as to thereby monitor the progression of the clear cell renal carcinoma in the human subject.
- This invention provides a method for detecting MN gene expression in a biological sample from human subject which comprises: (a) extracting mRNA from the sample; (b)contacting the MRNA from step (a) with reverse transcriptase under conditions allowing for the production of CDNA; (c)contacting the cDNA produced from step (b) with a pair of polymerase chain reaction oligonucleotide primers capable of specifically hybridizing with DNA encoding MN; (d) contacting the composition resulting from step (c) with DNA polymerase under conditions allowing for the extension of the primers so as to amplify a DNA molecule having the sequence flanked by the primers; and (e) detecting the amplified DNA from step (d), thereby detecting MN expression in the biological sample from the subject.
- the pair of primers in step (c) are 5'-GGG ACA AAG AAG GGG ATG AC-3' (SEQ ID NO:1) and 5'-AAA GGC GCT GAG GTG AA-3' (SEQ ID NQ:2).
- the biological sample is a peripheral blood sample.
- the renal cell carcinoma is clear cell carcinoma.
- step (d) is repeated 35 times.
- the amplified DNA detected is 386 base pairs long.
- the cDNA molecule encoding a portion of the MN protein is detected by: (a) loading the composition of step (e) onto a gel; (b) electrophoresing the cDNA of the composition into the gel; (c) ethidium bromide staining the cDNA inside the gel; and (d) visualizing the ethidium bromide stained cDNA under ultraviolet light, thereby detecting the cDNA molecule encoding a portion of the MN protein.
- the cDNA molecule encoding a portion of the MN protein is detected by: (a) loading the composition of step (e) onto a gel; (b) electrophoresing the cDNA of the composition into the gel; (c) Southern blotting the cDNA inside the gel to a solid support; (d) hybridizing the blotted cDNA on the solid support with a labeled MN DNA probe; and (e) visualizing the labeled MN DNA probe, thereby detecting the cDNA molecule encoding a portion of the MN protein.
- the labeled probe comprises a single-stranded probe 386 nucleotides in length and having a sequence complementary to the amplified cDNA.
- the labeled probe is radiolabeled with 32 P.
- This invention provides a method for the detection of MN gene expression in a biological sample from a human subject which comprises: (a) extracting mRNA from the sample; (b) contacting the MRNA from step (a) with reverse transcriptase under conditions allowing for the production of cDNA; (c) contacting the cDNA from step (b) with a pair of polymerase chain reaction oligonucleotide primers capable of specifically hybridizing with DNA encoding MN; (d) contacting the composition from step (c) with DNA polymerase under conditions allowing for the extension of the primers; and (e) detecting the composition from step (d), thereby detecting MN expression in the biological sample from the subject.
- This invention provides a method of diagnosing a renal cell carcinoma in a sample from a human subject which comprises: (a) extracting mRNA molecules from the peripheral blood; (b) amplifying a cDNA molecule encoding the MN protein which comprises: (i) contacting the mRNA molecule extract with a nucleic acid molecule primer capable of specifically hybridizing to a nucleic acid sequence site included within the mRNA encoding the MN protein under conditions allowing the primer to specifically hybridize to the MRNA encoding the MN protein; (ii) contacting the composition produced by (i) with reverse transcriptase under conditions allowing the reverse transcriptase to transcribe a single-stranded cDNA molecule copy of the mRNA molecule encoding the MN protein; (iii) heat denaturing the cDNA and mRNA molecule of the composition produced by step (ii); (iv) contacting the composition produced by step (iii) with a first primer capable of specifically hybridizing to a first
- This invention provides a method of monitoring the effect of a therapeutic intervention on the progression of a renal cell carcinoma in a sample from a human subject which comprises: (a) extracting mRNA molecules from the peripheral blood; (b) amplifying a cDNA molecule encoding the MN protein which comprises: (i) contacting the mRNA molecule extract with a nucleic acid molecule primer capable of specifically hybridizing to a nucleic acid sequence site included within the mRNA encoding the MN protein under conditions allowing the primer to specifically hybridize to the mRNA encoding the MN protein; (ii) contacting the composition produced by (i) with reverse transcriptase under conditions allowing the reverse transcriptase to transcribe a single-stranded cDNA molecule copy of the mRNA molecule encoding the MN protein; (iii) heat denaturing the cDNA and mRNA molecule of the composition produced by step (ii); (iv) contacting the composition produced by step (iii) with a
- This invention provides a method of determining the stage of a renal cell carcinoma in a sample from a human subject which comprises: (a) extracting mRNA molecules from the sample; (b) amplifying a cDNA molecule encoding the MN protein which comprises: (i) contacting the mRNA molecule extract with a nucleic acid molecule primer capable of specifically hybridizing to a nucleic acid sequence site included within the MRNA encoding the MN protein under conditions allowing the primer to specifically hybridize to the mRNA encoding the MN protein; (ii) contacting the composition produced by (i) with reverse transcriptase under conditions allowing the reverse transcriptase to transcribe a single-stranded cDNA molecule copy of the mRNA molecule encoding the MN protein; (iii) heat denaturing the cDNA and mRNA molecule of the composition produced by step (ii); (iv) contacting the composition produced by step (iii) with a first primer capable of specifically hybridizing to
- repeating steps (vi) through (viii) for a sufficient number of times means a number large enough to allow detection of the amplified cDNA by standard methods.
- Such number of times in a PCR reaction for amplification sufficient to detect amplified cDNA by standard methods including ethidium bromide staining or Southern blotting, is typically 30 times.
- a preferred number of times is often 20 to 40 times. In the present invention, 35 times is most preferred. However, a number of times as low as 15 and as high as 100 or more may also achieve amplification sufficient to detect the cDNA of interest.
- the renal cell carcinoma detected is clear cell carcinoma.
- the therapeutic intervention comprises radical nephrectomy.
- the therapeutic intervention comprises any one or more of the following immunotherapies: (a) interleukin-2 therapy; (b) interferon; (c) cellular immune therapy; or (d) monoclonal antibody therapy (e.g. a monoclonal antibody recognizing G250 and a cytotoxic agent conjugated thereto).
- the therapeutic intervention comprises chemotherapy or radiation therapy.
- the cDNA molecule encoding a portion of the MN protein is detected by: (a) loading the composition of step (ix) onto a gel; (b) electrophoresing the cDNA into the gel; (c) ethidium bromide staining the cDNA inside the gel; (d) visualizing the ethidium bromide stained cDNA under ultraviolet light, thereby detecting the cDNA molecule encoding a portion of the MN protein.
- the cDNA molecule encoding a portion of the MN protein is detected by: (a) loading the composition of step (ix) onto a gel; (b) electrophoresing the cDNA into the gel; (c) Southern blotting the cDNA inside the gel to a solid support such as a nylon or nitrocellulose membrane; (d) hybridizing the blotted CDNA with a radiolabeled MN DNA probe; and (e) visualizing the radiolabeled MN DNA probe by autoradiography, thereby detecting the cDNA molecule encoding a portion of the MN protein.
- This method is particularly useful for detection of MN expression in samples, such as human peripheral blood, which may have a low abundance of MN.
- the first primer of the above-described PCR methods comprises a nucleic acid molecule with a nucleotide sequence of 5'-GGG ACA AAG AAG GGG ATG AC-3' (SEQ ID NO:1) and the second primer comprises a nucleic acid molecule with a nucleotide sequence of 5'-AAA GGC GCT GAG GTG AA-3' (SEQ ID NO:2).
- the amplified MN cDNA detected is 386 base pairs long.
- the sample is peripheral blood.
- the amplified MN cDNA is detected by ethidium bromide staining. In another embodiment, the amplified MN cDNA is detected by Southern blotting and hybridization to a radiolabeled cDNA probe encoding a 386 nucleotide cDNA fragment. In another embodiment, the radiolabel is 32 P.
- MN is a 51 kd transmembrane glycoprotein that is associated with a malignant phenotype in human gynecological tumors.
- RT-PCR reverse transcriptase polymerase chain reaction
- the RT-PCR assay allowed us to identify the expected 386 bp product when applied to Hela cell RNA (human cervical cancer).
- Hela cell RNA human cervical cancer
- the product was cloned and sequenced and confirmed as MN.
- Normal human kidney, intestine, blood and cultured fibroblasts were negative for MN expression by RT-PCR as was the prostate cancer cell line, LNCaP.
- four of five primary renal tumors were positive as well as three human renal cancer cell lines of interest, the three positive renal cell lines were also found to stain for the renal tumor marker G250, whereas three additional cell lines that were negative for MN did not stain for G250.
- MN expression was never found in benign tissues, it was frequently found in renal cell carcinoma. Our results suggest that the MN gene is tumor-cell-specific. Therefore, detection of MN expression may be useful in a molecular staging assay for renal cell cancer.
- MN is a cell surface antigen originally detected in human HeLa cells. Although it is also expressed in normal gastric mucosa, this antigen was previously found to be expressed in cells with a malignant phenotype in certain tissues of the female genital tract (cervix and ovary).
- oligonucleotide primer set specific for the human nucleotide sequence encoding MN we performed RT-PCR assays on RNA extracted from human cell lines and tissues to evaluate whether this marker is expressed at sites other than normal gastric mucosa and malignant cervix and ovary.
- Complementary DNA libraries derived from normal human heart, lung, kidney, prostate, peripheral blood, brain, placenta and muscle were all negative for MN expression.
- RNA extracted from liver and pancreatic tissue was positive for MN expression.
- Three of six renal cancer cell lines tested revealed MN expression.
- 12 out of 18 samples of human renal cell carcinoma tissue tested positive for MN, all 12 of which were clear cell adenocarcinomas.
- this survey identified a unique association of MN expression with renal cell cancers, especially those of the clear cell variety, indicating that MN is a useful marker for the diagnosis, staging and therapeutic monitoring of renal cell carcinoma in humans.
- Tissues were snap-frozen in liquid nitrogen and then stored at -80° C. Frozen sections of each specimen were cut and analyzed to confirm the appropriate presence or absence of renal cell cancer.
- RNA extraction Eight milliliters of peripheral blood was obtained from normal healthy male and female volunteers. Nucleated cells were separated in a ficoll gradient cell separation tube (Vacutainer #362761, Becton-Dickinson, Piscataway, N.J.) as previously described (6). The nucleated cells were then removed from the buffy coat fraction and washed once in phosphate-buffered saline and pelleted. Cell pellets were stored at -80° C. prior to RNA extraction.
- RNA extraction was performed using a guanidinium thiocyanate--phenol/chloroform technique (14) utilizing the RNazole B reagent of Tel-Test (Friendswood, Tex.). Cells grown in culture were scraped into medium, centrifuged, washed, and directly homogenized (using a Brinkman Tissue Disrupter) with 2 ⁇ l RNazole per 20mm 2 of cells growing in a monolayer. Frozen tissues were pulverized under liquid nitrogen and the frozen powder was likewise extracted with RNazole B. The RNA pellet obtained after isopropanol and ethanol precipitation was dried under a vacuum drier and resuspended in 50 ⁇ l of RNase-free water. RNA yield was quantified using ultraviolet spectrophotometry at 260 nm. RNA specimens were stored in aliquots at -80° C. prior to reverse transcription.
- RNA was added to 0.5 ⁇ g of oligo dT primer (GIBCO BRL Life Technologies) and brought to a final volume of 20 ⁇ l. The samples were placed at 65° C. for 5 minutes and then cooled on ice. The downstream or 3' PCR primer (see below) may also be used for priming the reverse transcription of mRNA into cDNA. The primer-RNA mixture was then combined with 200 units of Moloney murine leukemia virus reverse transcriptase (RT) (Superscript II, GIBCO BRL) and 10 units of recombinant RNase inhibitor.
- RT Moloney murine leukemia virus reverse transcriptase
- the master mixture was completed by adding 1 mM dNTPs, 50 mM Tris-HCl, 75 mM potassium chloride, 3 mM magnesium chloride and 10 mM dithiothreitol according to manufacturer's instructions.
- the reverse transcription reaction was then carried out at 37° C. for 90 minutes. Samples were stored at -20° C.
- Oligonucleotide primers specific for MN CDNA were designed using the Oligo Software application system.
- the 5' primer was designed to span the splice junction between the first and second exons within the MN genomic sequence. This design prevents amplification of any product from genomic MN DNA that might contaminate RNA specimens.
- PCR was performed on the cDNA with a denaturing temperature of 94° C. (1 min), annealing temperature of 57° C. (1 min) and an extension temperature of 72° C. (1 min) for 35 cycles using a Perkin Elmer-Cetus Thermocycler 7,000.
- a separate portion of cDNA was amplified using primers specific for human glucose-3-phosphate dehydrogenase.
- Positive and negative PCR controls were provided by HeLa cell RNA (strongly positive for MN) , which was reverse transcribed to cDNA (to provide a positive control) or not reverse transcribed (to provide a negative control or a control for contamination).
- PCR products were then separated by electrophoresis on a 1% agarose gel. DNA fragments were visualized and photographed under UV light subsequent to ethidium bromide staining.
- the expected band for MN is 386 bp and was identified by co-migration of a DNA marker ladder electrophoresed in an adjacent lane.
- the positive 386 bp DNA fragment was excised from the agarose gel (subsequent to RT-PCR assay of HeLa cell RNA) and directly cloned into the TA cloning vector (Invitrogen, San Diego, Calif.) according to the manufacturer's instructions.
- the cloned 386 bp fragment was sequenced using conventional dideoxy-nucleotide chain termination techniques to confirm identity with the.MN transcript.
- nylon or nitrocellulose membranes are suitable for the Southern blot DNA transfer.
- an overnight transfer to a nylon membrane was performed.
- the membrane was first prehybridized in a stock prehybridization DNA solution and then hybridized at 68° C. for 12 hours in the presence of the 32 P-radiolabeled 386 base single-stranded MN DNA probe. Finally, the membrane was exposed to autoradiographic film for 12 hours to visualize the band.
- oligonucleotide primers that were designed to amplify a 386 bp portion of MN cDNA
- the PCR reaction products were electrophoresed on a 1% agarose gel. Ethidium bromide staining of this gel identified the 386 bp band characteristic of amplification of MN cDNA.
- the identity of the 386 bp PCR product as a fragment of MN cDNA was confirmed by cloning and sequencing the amplified DNA fragment.
- the sequence of this product was identical to the region of the MN cDNA from position 433 to position 819 of the reported cDNA sequence (12), the region that the primers were designed to amplify.
- a negative control tested with this RT-PCR assay using non-reverse-transcribed HeLa cell RNA, did not show any amplified products.
- a direct PCR amplification of purified human genomic DNA did not show any amplified products.
- the genomic DNA-based amplification product exceeds the optimum length for amplification of most PCR-based detection systems.
- Representative cDNA libraries were obtained from 9 different normal human tissues. These cDNA libraries were directly amplified using the MN primers in a standard PCR reaction. The MN PCR product was not detected in the reaction products from normal human nucleated blood cells, heart, lung, brain, skeletal muscle, placenta or kidney. The 386 bp band characteristic of MN cDNA was detected, however, in the reaction products of human liver and pancreas CDNA libraries (FIG. 1).
- renal cell carcinoma is thought to arise from cells of the proximal tubule (16).
- renal cancer cells share many surface markers with renal tubular cells, no single protein has proven effective as a serum marker in renal cancer. Serum levels of such proteins as erythropoietin and ferritin have been used to follow patients after nephrectomy to detect recurrent disease (17,18,19,20). However, these markers have shown limited clinical usefulness in the diagnosis and staging of renal cancer.
- the gene product known as MN is an important marker of certain types of renal cell cancer in humans.
- MN The novel tumor-associated protein known as MN was first isolated from the human cervical cancer cell line HeLa by Der and Stanbridge (10). MN has subsequently been characterized and found to be a 51 kilodalton cell surface protein. The complementary DNA sequence and intron-exon map of the MN coding region have also recently been elucidated (12,21). The MN gene appears to be a member of the carbonic anhydrase family. Its precise role in oncogenesis remains unclear. However, this protein is able to induce a malignant phenotype in cell culture experiments. When MN cDNA was transfected into NIH-3T3 cells, the cells demonstrated loss of cell-cell growth inhibition, failed to grow in monolayers, and acquired a spindle-shaped morphology.
- MN messenger RNA in tissue from human liver and pancreas has not been previously described. However, MN is expressed in gastric mucosa of normal subjects and is perhaps localized to tissues of the upper gastrointestinal tract.
- MN detected in 3 human renal tumor cell lines (SKRC-01, SKRC-08 and SKRC-09) is relevant because these cell lines have previously been shown to express a renal cell carcinoma-specific cell surface marker known as G250 (16).
- G250 renal cell carcinoma-specific cell surface marker
- the absence of MN expression in SKRC-17, SKRC-39 and SKRC-42 is consistent with this association because these three cell lines have been shown to be G250-negative.
- the G250 gene has been cloned and sequenced and preliminary analysis indicates homology to, if not identity with, the MN gene (22) The precise relationship between MN gene expression and G250 expression, however, will require further study.
- Serum ferritin as a clinical marker for renal cell carcinoma influence of tumor volume, Urology 45, 211.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
TABLE 1 ______________________________________ MN expression Pt Histology Grade Tumor Normal Kidney ______________________________________ 1 Clear 2 pos neg 2 Clear 1pos neg 3 Clear 2 pos neg 4 Clear 2/3 pos neg 5 Clear 2/3 pos neg 6 Clear 2 pos neg 7 Clear 2pos neg 8 Clear 1 pos neg 9 Clear 2 pos neg 10Clear 3 pos N/A 11 Clear 2 pos N/A 12 Clear 2 pos N/A 13 Gran'r/Pap'y 1/3 neg neg 14 Granular 1 neg N/A 15 Granular/Clear 2 neg N/A 16 Papillary 2 neg N/A 17 Gran'r/Pap'y 2/3 neg N/A ______________________________________ Abbreviations used in Table 1. Pt = Patient. Gran'r = Granular. Pap'y = Papillary.
__________________________________________________________________________ # SEQUENCE LISTING - - - - (1) GENERAL INFORMATION: - - (iii) NUMBER OF SEQUENCES: 2 - - - - (2) INFORMATION FOR SEQ ID NO:1: - - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - - (ii) MOLECULE TYPE: DNA - - (iii) HYPOTHETICAL: N - - (iv) ANTI-SENSE: N - - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: - - GGGACAAAGA AGGGGATGAC - # - # - # 20 - - - - (2) INFORMATION FOR SEQ ID NO:2: - - (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - - (ii) MOLECULE TYPE: DNA - - (iii) HYPOTHETICAL: N - - (iv) ANTI-SENSE: N - - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: - - AAAGGCGCTG AGGTGAA - # - # - # 17 __________________________________________________________________________
Claims (6)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/839,698 US6087098A (en) | 1997-04-15 | 1997-04-15 | Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma |
PCT/US1998/007719 WO1998046798A1 (en) | 1997-04-15 | 1998-04-15 | Enhanced reverse transcriptase polymerase chain assay to detect mn in patients with renal cell carcinoma |
AU74671/98A AU7467198A (en) | 1997-04-15 | 1998-04-15 | Enhanced reverse transcriptase polymerase chain assay to detect mn in patien ts with renal cell carcinoma |
US09/403,145 US6451532B1 (en) | 1997-04-15 | 1999-10-15 | Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/839,698 US6087098A (en) | 1997-04-15 | 1997-04-15 | Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/007719 Continuation-In-Part WO1998046798A1 (en) | 1997-04-15 | 1998-04-15 | Enhanced reverse transcriptase polymerase chain assay to detect mn in patients with renal cell carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
US6087098A true US6087098A (en) | 2000-07-11 |
Family
ID=25280427
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/839,698 Expired - Lifetime US6087098A (en) | 1997-04-15 | 1997-04-15 | Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma |
US09/403,145 Expired - Fee Related US6451532B1 (en) | 1997-04-15 | 1999-10-15 | Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/403,145 Expired - Fee Related US6451532B1 (en) | 1997-04-15 | 1999-10-15 | Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma |
Country Status (3)
Country | Link |
---|---|
US (2) | US6087098A (en) |
AU (1) | AU7467198A (en) |
WO (1) | WO1998046798A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6538029B1 (en) * | 2002-05-29 | 2003-03-25 | Cell Pathways | Methods for treatment of renal cell carcinoma |
US20040110221A1 (en) * | 2002-11-21 | 2004-06-10 | Wyeth | Methods for diagnosing RCC and other solid tumors |
US6770438B2 (en) * | 1992-03-11 | 2004-08-03 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
US20050079513A1 (en) * | 2003-10-14 | 2005-04-14 | Ronald Levy | Classification of patients having diffuse large B-cell lymphoma based upon gene expression |
US20050112634A1 (en) * | 2003-09-19 | 2005-05-26 | Woudenberg Timothy M. | High density sequence detection methods and apparatus |
US20050131847A1 (en) * | 1998-05-01 | 2005-06-16 | Jason Weston | Pre-processed feature ranking for a support vector machine |
US20050255485A1 (en) * | 2004-05-14 | 2005-11-17 | Livak Kenneth J | Detection of gene duplications |
US20060003337A1 (en) * | 2004-06-30 | 2006-01-05 | John Brandis | Detection of small RNAS |
US20060024690A1 (en) * | 2003-09-19 | 2006-02-02 | Kao H P | Normalization of data using controls |
US20060194211A1 (en) * | 2003-04-29 | 2006-08-31 | Burczynski Michael E | Methods for prognosis and treatment of solid tumors |
US20060262877A1 (en) * | 2001-12-21 | 2006-11-23 | Digital Fountain, Inc. | Multi-stage code generator and decoder for communication systems |
US20080233576A1 (en) * | 1998-05-01 | 2008-09-25 | Jason Weston | Method for feature selection in a support vector machine using feature ranking |
EP2031070A1 (en) | 2002-12-04 | 2009-03-04 | Applera Corporation | Multiplex amplification of polynucleotides |
US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
US7643943B2 (en) | 2003-02-11 | 2010-01-05 | Wyeth Llc | Methods for monitoring drug activities in vivo |
US20100056611A1 (en) * | 2006-10-12 | 2010-03-04 | Jaromir Pastorek | MN/CA9 Splice Variants |
EP2208797A2 (en) | 2004-03-01 | 2010-07-21 | Applied Biosystems, LLC | Methods, compositions and kits for use in polynucleotide amplification |
US20110078099A1 (en) * | 2001-05-18 | 2011-03-31 | Health Discovery Corporation | Method for feature selection and for evaluating features identified as significant for classifying data |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935344A (en) * | 1984-04-30 | 1990-06-19 | Sloan-Kettering Institute For Cancer Research | Method for characterizing types of renal carcinoma and prognosis |
US5387676A (en) * | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
-
1997
- 1997-04-15 US US08/839,698 patent/US6087098A/en not_active Expired - Lifetime
-
1998
- 1998-04-15 WO PCT/US1998/007719 patent/WO1998046798A1/en active Application Filing
- 1998-04-15 AU AU74671/98A patent/AU7467198A/en not_active Abandoned
-
1999
- 1999-10-15 US US09/403,145 patent/US6451532B1/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935344A (en) * | 1984-04-30 | 1990-06-19 | Sloan-Kettering Institute For Cancer Research | Method for characterizing types of renal carcinoma and prognosis |
US5387676A (en) * | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
Non-Patent Citations (46)
Title |
---|
Bander et al. (1989) "Analysis of a Mouse Monoclonal Antibody That Reacts with a Specific Region of the Human Proximal Tubule and Subsets Renal Cell Carcinoma, " Cancer Research 49:6774-6780 (Exhibit 2). |
Bander et al. (1989) Analysis of a Mouse Monoclonal Antibody That Reacts with a Specific Region of the Human Proximal Tubule and Subsets Renal Cell Carcinoma, Cancer Research 49:6774 6780 (Exhibit 2). * |
Brewer et al. (1996) "A Study of Biomarkers in Cervical Carcinoma and Clinical Correlation of the Novel Biomarker MN, " Gynecol. Oncol. 63(3): 337-344 (Exhibit 3). |
Brewer et al. (1996) A Study of Biomarkers in Cervical Carcinoma and Clinical Correlation of the Novel Biomarker MN, Gynecol. Oncol. 63(3): 337 344 (Exhibit 3). * |
Der et al. (1981) "A Tumor-specific Membrane Phosphoprotein Marker in Human Cell Hybrids," Cell 26:429-438 (Exhibit 4). |
Der et al. (1981) A Tumor specific Membrane Phosphoprotein Marker in Human Cell Hybrids, Cell 26:429 438 (Exhibit 4). * |
Kranenborg et al. (1995) "Development and Characterization of Anti-Renal Cell Carcinoma X Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma," Cancer Res. 55(23):5864s-5867s. (Exhibit 5). |
Kranenborg et al. (1995) Development and Characterization of Anti Renal Cell Carcinoma X Antichelate Bispecific Monoclonal Antibodies for Two Phase Targeting of Renal Cell Carcinoma, Cancer Res. 55(23):5864s 5867s. (Exhibit 5). * |
Kusama et al. (1991) "Tumor Markers in Human Renal Cell Carcinoma," Tumor Biol 12:189-197 (Exhibit 6). |
Kusama et al. (1991) Tumor Markers in Human Renal Cell Carcinoma, Tumor Biol 12:189 197 (Exhibit 6). * |
Liao et al. (1994) "Identification of the MN Antigen as a Diagnostic Biomarker of Cervical Intraepithelial Squamous and Glandular Neoplasia and Cervical Carcinomas," Am. J. Pathol. 145(3):598-609 (Exhibit 7). |
Liao et al. (1994) Identification of the MN Antigen as a Diagnostic Biomarker of Cervical Intraepithelial Squamous and Glandular Neoplasia and Cervical Carcinomas, Am. J. Pathol. 145(3):598 609 (Exhibit 7). * |
McKiernan, J. M. et al., "Expression of Tumor-associated Gene MN: A potential biomarker for human renal cell carcinoma"; Cancer Research, vol. 57, pp. 2362-2365, Jun. 15, 1997. |
McKiernan, J. M. et al., Expression of Tumor associated Gene MN: A potential biomarker for human renal cell carcinoma ; Cancer Research, vol. 57, pp. 2362 2365, Jun. 15, 1997. * |
Olive, Colleen et al., "Characterisation of gamma delta T cells in renal cell carcinoma patients by polymerase chain reaction analysis of T cell receptor transcripts"; Cancer Immunol. Immunother. vol. 44, pp. 27-34, Mar. 1, 1997. |
Olive, Colleen et al., Characterisation of gamma delta T cells in renal cell carcinoma patients by polymerase chain reaction analysis of T cell receptor transcripts ; Cancer Immunol. Immunother. vol. 44, pp. 27 34, Mar. 1, 1997. * |
Oosterwijk et al. (1986) "Monoclonal Antibody G 250 Recognizes a Determinant Present in Renal-Cell Carcinoma and Absent from Normal Kidney," Intl. J. Cancer 38:489-494 (Exhibit 9). |
Oosterwijk et al. (1986) Monoclonal Antibody G 250 Recognizes a Determinant Present in Renal Cell Carcinoma and Absent from Normal Kidney, Intl. J. Cancer 38:489 494 (Exhibit 9). * |
Oosterwijk et al. (1993) "Antibody Localization in Human Renal Cell Carcinoma: A Phase I Study of Monoclonal Antibody G250," J. Clin. Oncol. 11(4):738-750. (Exhibit 8). |
Oosterwijk et al. (1993) Antibody Localization in Human Renal Cell Carcinoma: A Phase I Study of Monoclonal Antibody G250, J. Clin. Oncol. 11(4):738 750. (Exhibit 8). * |
Oosterwijk et al. (1995) "Radiolabled Monoclonal Antibody G250 in Renal-Cell Carcinoma," World J. Urol. 13(3):186-190 (Exhibit 11). |
Oosterwijk et al. (1995) "The Use of Monoclonal Antibody G250 in the Therapy of Renal-Cell Carcinoma," Semin. Oncol. 22(1):34-41 (Exhibit 12). |
Oosterwijk et al. (1995) Radiolabled Monoclonal Antibody G250 in Renal Cell Carcinoma, World J. Urol. 13(3):186 190 (Exhibit 11). * |
Oosterwijk et al. (1995) The Use of Monoclonal Antibody G250 in the Therapy of Renal Cell Carcinoma, Semin. Oncol. 22(1):34 41 (Exhibit 12). * |
Oosterwijk et al. (1996) "Molecular Characterization of the Renal Cell Carcinoma-associated Antigen G250," Proc. Am. Urol. Assn. 155, 542A (abstract No. 925) (Exhibit 10). |
Oosterwijk et al. (1996) Molecular Characterization of the Renal Cell Carcinoma associated Antigen G250, Proc. Am. Urol. Assn. 155, 542A (abstract No. 925) (Exhibit 10). * |
Opavsk y et al. (1996) Human Mn/ca9 Gene, a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain Relationships, Genomics 33:480 487 (Exhibit 13). * |
Opavsky et al. (1996) "Human Mn/ca9 Gene, a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain Relationships," Genomics 33:480-487 (Exhibit 13). |
Pastorek et al. (1994) "Cloning and Characterization of MN, a Human Tumor-associated Protein with a Domain Homologous to Carbonic Anhydrase and a Putative Helix-loop-helix Dna Binding Segment," Oncogene 9:2877-2888 (Exhibit 14). |
Pastorek et al. (1994) Cloning and Characterization of MN, a Human Tumor associated Protein with a Domain Homologous to Carbonic Anhydrase and a Putative Helix loop helix Dna Binding Segment, Oncogene 9:2877 2888 (Exhibit 14). * |
Pastorekova et al. (1997) "Carbonic Anhydrase IX, MN/CA IX: Analysis of Stomach Complementary DNA Sequence and Expression in Human and Rat Alimentary Tracts," Gastroenterology 112(2):398-408 (Exhibit 15). |
Pastorekova et al. (1997) Carbonic Anhydrase IX, MN/CA IX: Analysis of Stomach Complementary DNA Sequence and Expression in Human and Rat Alimentary Tracts, Gastroenterology 112(2):398 408 (Exhibit 15). * |
Steffens et al. (1997) "Targeting of Renal Cell Carcinoma with Iodine-131-Labeled Chimeric Monoclonal Antibody G250," J. Clin. Oncol. 15(4):1529-37 (Exhibit 16). |
Steffens et al. (1997) Targeting of Renal Cell Carcinoma with Iodine 131 Labeled Chimeric Monoclonal Antibody G250, J. Clin. Oncol. 15(4):1529 37 (Exhibit 16). * |
Surfus et al. (1996) "Anti-Renal-Cell Carcinoma Chimeric Antibody G250 Facilitates Antibody-Dependent Cellular Cytotoxicity with In Vitro and In Vivo Interleukin-2-Activated Effectors," J. Immunother Emphasis Tumor Immunol. 19(3):184-191(Exhibit 17). |
Surfus et al. (1996) Anti Renal Cell Carcinoma Chimeric Antibody G250 Facilitates Antibody Dependent Cellular Cytotoxicity with In Vitro and In Vivo Interleukin 2 Activated Effectors, J. Immunother Emphasis Tumor Immunol. 19(3):184 191(Exhibit 17). * |
Uemura et al. (1994) "Immunization with Anti-Idiotype Monoclonal Antibodies Bearing the Internal Image of the Renal-Cell Carcinoma-Associated Antigen G250 Induces Specific Cellular Immune Responses," Int. J. Cancer 59(6):802-807 (Exhibit 18). |
Uemura et al. (1994) "Internal Image Anti-Idiotype Antibodies Related to Renal-Cell Carcinoma-Associated Antigen G250," Int. J. Cancer 56(4): 609-614 (Exhibit 19). |
Uemura et al. (1994) "Vaccination with Anti-Idiotype Antibodies Mimicking a Renal Cell Carcinoma-Associated Antigen Induces Tumor Immunity," Int. J. Cancer 58(4): 555-561 (Exhibit 20). |
Uemura et al. (1994) Immunization with Anti Idiotype Monoclonal Antibodies Bearing the Internal Image of the Renal Cell Carcinoma Associated Antigen G250 Induces Specific Cellular Immune Responses, Int. J. Cancer 59(6):802 807 (Exhibit 18). * |
Uemura et al. (1994) Internal Image Anti Idiotype Antibodies Related to Renal Cell Carcinoma Associated Antigen G250, Int. J. Cancer 56(4): 609 614 (Exhibit 19). * |
Uemura et al. (1994) Vaccination with Anti Idiotype Antibodies Mimicking a Renal Cell Carcinoma Associated Antigen Induces Tumor Immunity, Int. J. Cancer 58(4): 555 561 (Exhibit 20). * |
Van Dijk et al. (1994) "Therapeutic Effects of Monoclonal Antibody G250, Interferons and Tumor Necrosis Factor, In Mice with Renal-Cell Carcinoma Xenografts," Int. J. Cancer 56(2):262-268 (Exhibit 21). |
Van Dijk et al. (1994) Therapeutic Effects of Monoclonal Antibody G250, Interferons and Tumor Necrosis Factor, In Mice with Renal Cell Carcinoma Xenografts, Int. J. Cancer 56(2):262 268 (Exhibit 21). * |
Zavada et al. (1993) "Expression of MaTu-MN Protein in Human Tumor Cultures and in Clinical Specimens," Int. J. Cancer 54(2): 268-274 (Exhibit 22). |
Zavada et al. (1993) Expression of MaTu MN Protein in Human Tumor Cultures and in Clinical Specimens, Int. J. Cancer 54(2): 268 274 (Exhibit 22). * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770438B2 (en) * | 1992-03-11 | 2004-08-03 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
US20050131847A1 (en) * | 1998-05-01 | 2005-06-16 | Jason Weston | Pre-processed feature ranking for a support vector machine |
US7475048B2 (en) * | 1998-05-01 | 2009-01-06 | Health Discovery Corporation | Pre-processed feature ranking for a support vector machine |
US20080233576A1 (en) * | 1998-05-01 | 2008-09-25 | Jason Weston | Method for feature selection in a support vector machine using feature ranking |
US7805388B2 (en) | 1998-05-01 | 2010-09-28 | Health Discovery Corporation | Method for feature selection in a support vector machine using feature ranking |
US20110106735A1 (en) * | 1999-10-27 | 2011-05-05 | Health Discovery Corporation | Recursive feature elimination method using support vector machines |
US20110119213A1 (en) * | 1999-10-27 | 2011-05-19 | Health Discovery Corporation | Support vector machine - recursive feature elimination (svm-rfe) |
US8095483B2 (en) | 1999-10-27 | 2012-01-10 | Health Discovery Corporation | Support vector machine—recursive feature elimination (SVM-RFE) |
US10402685B2 (en) | 1999-10-27 | 2019-09-03 | Health Discovery Corporation | Recursive feature elimination method using support vector machines |
US7970718B2 (en) | 2001-05-18 | 2011-06-28 | Health Discovery Corporation | Method for feature selection and for evaluating features identified as significant for classifying data |
US20110078099A1 (en) * | 2001-05-18 | 2011-03-31 | Health Discovery Corporation | Method for feature selection and for evaluating features identified as significant for classifying data |
US20060262877A1 (en) * | 2001-12-21 | 2006-11-23 | Digital Fountain, Inc. | Multi-stage code generator and decoder for communication systems |
US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
US6538029B1 (en) * | 2002-05-29 | 2003-03-25 | Cell Pathways | Methods for treatment of renal cell carcinoma |
US7611839B2 (en) | 2002-11-21 | 2009-11-03 | Wyeth | Methods for diagnosing RCC and other solid tumors |
US20040110221A1 (en) * | 2002-11-21 | 2004-06-10 | Wyeth | Methods for diagnosing RCC and other solid tumors |
EP2031070A1 (en) | 2002-12-04 | 2009-03-04 | Applera Corporation | Multiplex amplification of polynucleotides |
EP3000899A1 (en) | 2002-12-04 | 2016-03-30 | Applied Biosystems, LLC | Multiplex amplification of polynucleotides |
US7643943B2 (en) | 2003-02-11 | 2010-01-05 | Wyeth Llc | Methods for monitoring drug activities in vivo |
US20060194211A1 (en) * | 2003-04-29 | 2006-08-31 | Burczynski Michael E | Methods for prognosis and treatment of solid tumors |
US20080032299A1 (en) * | 2003-04-29 | 2008-02-07 | Wyeth | Methods for prognosis and treatment of solid tumors |
US20060024690A1 (en) * | 2003-09-19 | 2006-02-02 | Kao H P | Normalization of data using controls |
US20050112634A1 (en) * | 2003-09-19 | 2005-05-26 | Woudenberg Timothy M. | High density sequence detection methods and apparatus |
US20070026453A1 (en) * | 2003-10-14 | 2007-02-01 | Ronald Levy | Classification of patients having diffuse large B-cell lymphoma based upon gene expresson |
US7332280B2 (en) | 2003-10-14 | 2008-02-19 | Ronald Levy | Classification of patients having diffuse large B-cell lymphoma based upon gene expression |
US7622253B2 (en) | 2003-10-14 | 2009-11-24 | Ronald Levy | Classification of patients having diffuse large b-cell lymphoma based upon gene expression |
US20050079513A1 (en) * | 2003-10-14 | 2005-04-14 | Ronald Levy | Classification of patients having diffuse large B-cell lymphoma based upon gene expression |
EP2208797A2 (en) | 2004-03-01 | 2010-07-21 | Applied Biosystems, LLC | Methods, compositions and kits for use in polynucleotide amplification |
US20100203525A1 (en) * | 2004-05-14 | 2010-08-12 | Life Technologies Corporation | Detection of gene duplications |
US20050255485A1 (en) * | 2004-05-14 | 2005-11-17 | Livak Kenneth J | Detection of gene duplications |
US20060003337A1 (en) * | 2004-06-30 | 2006-01-05 | John Brandis | Detection of small RNAS |
US20100056611A1 (en) * | 2006-10-12 | 2010-03-04 | Jaromir Pastorek | MN/CA9 Splice Variants |
Also Published As
Publication number | Publication date |
---|---|
US6451532B1 (en) | 2002-09-17 |
WO1998046798A1 (en) | 1998-10-22 |
AU7467198A (en) | 1998-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6087098A (en) | Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma | |
McKiernan et al. | Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma | |
US7709233B2 (en) | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer | |
Gress et al. | Identification of genes with specific expression in pancreatic cancer by cDNA representational difference analysis | |
US6607898B1 (en) | Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum | |
Matsumura et al. | Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities | |
EP0868529B1 (en) | Method for detection of ki-ras mutations and kit to perform it | |
EP0284362A2 (en) | Molecular markers | |
WO1998046798A9 (en) | Enhanced reverse transcriptase polymerase chain assay to detect mn in patients with renal cell carcinoma | |
Nanus et al. | Infrequent ras oncogene point mutations in renal cell carcinoma | |
JPH044898A (en) | Detection of deficiency of wild type p53 gene | |
CA2187775A1 (en) | Method for molecular staging of prostate cancer | |
US20090087843A1 (en) | Molecular markers | |
EP1086218A2 (en) | Genes and gene expression products that are differentially regulated in prostate cancer | |
CA2451483C (en) | Methods for detecting and monitoring cox-2 rna in plasma and serum | |
Miyake et al. | Highly specific and sensitive detection of malignancy in urine samples from patients with urothelial cancer by CD44v8–10/CD44v10 competitive RT‐PCR | |
JP2800850B2 (en) | Methods for detecting neoplasia | |
US5670318A (en) | Human BC200 RNA probes and a method of screening for breast cancer using the probes therefor | |
CA2067114A1 (en) | Sensitive method for measurement of chimeric transcripts of dna containing translocations | |
US5952200A (en) | Method of diagnosing cancer in human cells using a reverse transcriptase-polymerase chain reaction for identifying the presence of stromelysin-3 | |
KR20210101179A (en) | Gender-specific markers for diagnosing prognosis and determining treatment strategies of patient of clear cell renal cell carcinoma | |
US7108977B2 (en) | Process for determining the tumoricidal potential of a sample the use of a nucleic acid which is downregulated in human tumor cells | |
US20100159464A1 (en) | Method for Detection of DNA Methyltransferase RNA in Plasma and Serum | |
JP2007510424A (en) | Molecular marker | |
FI108301B (en) | Diagnostic method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COLUMBIA UNIVERSITY, THE TRUSTEES OF, IN THE CITY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCKIERNAN, JAMES M.;SAWCZUK, IHOR S.;BUTTYAN, RALPH;REEL/FRAME:009080/0820;SIGNING DATES FROM 19980313 TO 19980316 |
|
AS | Assignment |
Owner name: CORNELL RESEARCH FOUNDATION, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BANDER, NEIL H.;REEL/FRAME:009078/0044 Effective date: 19980316 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:CORNELL UNIVERSITY;REEL/FRAME:021372/0254 Effective date: 20001024 |
|
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PMFG); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
REIN | Reinstatement after maintenance fee payment confirmed | ||
PRDP | Patent reinstated due to the acceptance of a late maintenance fee |
Effective date: 20120817 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
SULP | Surcharge for late payment | ||
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20120711 |